IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Clinical trial NCT03381183 · COMPLETED

Trial details

NCT number: NCT03381183
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Metastatic Squamous Cell Carcinoma Oral Cavity Squamous Cell Carcinoma Oropharynx Squamous Cell Carcinoma Paranasal Sinus Squamous Cell Carcinoma Hypopharynx Squamous Cell Carcinoma Larynx Squamous Cell Carcinoma

Start date: 2019-08-21
Primary completion: 2022-05-12
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.